심장내 초음파 검사(ICE)는 경흉부 심장내 초음파 검사나 "표준" 심장내 초음파 검사와 마찬가지로 음파를 이용하여 심장의 이미지를 생성합니다. 그러나 심혈관 초음파 검사는 초음파 센서가 달린 작은 카테터를 심장에 삽입하여 심장의 완벽한 이미지를 얻어 당뇨병성 심장 질환의 진단 및 관리에 도움을 줄 수 있습니다.
심장내 초음파(ICE)는 심방중격결핍증(ASD), 심방세동(PFO), 심실중격결핍증(VSD)의 폐쇄술을 보조하기 위해 일반적으로 사용되는 고유한 카테터 영상 기술로, 몇 년 전까지만 해도 개심술로만 시행되었습니다. 심장내 초음파는 구조적 심장 질환 및 부정맥에 대한 경카테터 삽입을 지시하기 위해 시술의 성공을 간소화하고 복잡성을 최소화하기 위해 널리 채택되고 있습니다.
심혈관계 질환의 증가, 합병, 인수, 제품 출시, 시장 개척, 인지도 향상 등이 예측 기간 동안 세계 심혈관 질환 사례 증가로 인해 심혈관 내시경 장비 시장의 성장을 촉진할 것으로 예상됩니다. 또한, 심혈관 내시경 장비의 연구 활동 활성화, 기술 발전, 자금 지원 등도 예측 기간 동안 세계 시장 성장에 기여할 것으로 예상됩니다.
다이나믹스
심혈관 질환의 유병률 증가
심혈관 질환 사례의 증가는 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상되는 주요 요인 중 하나입니다. 예를 들어, 유럽심장혈관학회에 따르면 ESC 회원국에서 매년 1,260만 명 이상이 CVD를 앓고 있습니다. 심혈관계 질환은 ESC 회원국의 남성 사망 원인 1위(39%)인 반면, ESC 회원국에서 매년 220만 명의 여성이 심혈관계 질환으로 사망하고 있으며, EU에서는 여성의 40%가 CVD로 사망하고 있습니다.
또한 영국심장재단이 2023년 4월에 발표한 영국 팩트시트에 따르면, 영국에서 약 760만 명이 심장 및 순환기 질환을 앓고 있으며, 고령화와 인구 증가, 심장 및 순환기 질환으로 인한 생존율 증가로 인해 이 숫자는 더 늘어날 수 있다고 합니다. 영국에서는 남성 약 400만 명, 여성 360만 명 이상이 심장 및 순환기 질환을 앓고 있으며, 영국 주민의 절반 이상이 일생 동안 심장 및 순환기 질환을 겪을 것으로 추정됩니다.
또한, 암이나 알츠하이머 환자 수와 비교했을 때, 영국에서는 약 2배의 사람들이 심장 및 순환기 질환을 앓고 있습니다. 심장 및 순환기 질환은 영국 전체 사망의 약 25%를 차지하며, 이는 연간 16만 명 이상, 매일 460명, 3분의 1이 사망하는 셈이며, 영국에서는 매년 약 48,000명의 75세 미만 인구가 심장 및 순환기 질환으로 사망하고 있습니다.
제품 승인 증가
또한, 명확한 규제 당국의 제품 승인 증가는 예측 기간 동안 세계 심내막 초음파 장치 시장의 성장에 기여할 것으로 예상됩니다. 예를 들어, 2022년 4월 프랭클린 마운틴 메디컬(Franklin Mountain Medical)은 특허받은 UltraNav Transseptal Catheter System의 FDA 승인을 획득했습니다. 이 듀얼 루멘 카테터는 하나의 듀얼 루멘 장치를 통해 ICE와 경중격 바늘 또는 카테터를 동시에 나란히 전달할 수 있어 경중격 천자를 통해 심혈관 카테터와 가이드와이어를 심실에 안정적으로 접근하고 전달할 수 있게 해줍니다. 합니다.
지멘스 헬시니어스는 2021년 6월, 구조적 심장 및 전기생리학적 수술에서 심장 해부학적 구조를 실시간으로 광각으로 볼 수 있는 영상 가이드인 AcuNav Volume ICE(심장내 초음파) 카테터에 대한 CE 마크를 획득했습니다. AcuNav Volume ICE는 20년간의 ICE 기술 혁신을 바탕으로 설계된 시장 최고의 Volume ICE 카테터입니다.
심장내 초음파 기기의 막대한 비용
고가의 심혈관 내시경 장비 및 카테터 비용은 예측 기간 동안 세계 심혈관 내시경 장비 시장의 성장을 저해할 것으로 예상됩니다. 예를 들어, 위상 배열 ICE 카테터 비용은 카테터 구매 수량에 따라 2,000달러에서 2,500달러까지 다양합니다. 마찬가지로 심장 3D 매핑 시스템의 평균 가격은 250,000-800,000달러입니다.
마찬가지로 Boston Scientific의 iLAB Ultrasound Imaging System for Intracardiac Imaging의 가격은 약 131,400달러입니다. 또한, 심강내 초음파 카테터 시스템의 평균 비용(미화 2,000-2,500달러)은 심강내 초음파의 일반적인 사용에 중요한 장벽이 되어 예측 기간 동안 세계 심강내 초음파 장비 시장의 수요를 둔화시켰습니다.
심장 전문의 인력 부족
심장 전문의 인력 부족은 예측 기간 동안 세계 심초음파 장비 시장의 성장을 저해할 것으로 예상됩니다. 예를 들어, 미국심장학회(American College of Cardiology Foundation)에 따르면, 심장병학 전문 분야는 증가하는 환자 수요를 충족시킬 수 있는 임상의가 충분하지 않아 우려의 위기에 처해 있습니다. 마찬가지로 유럽심장학회에 따르면, 고소득 국가의 인구 100만 명당 순환기 전문의 수는 평균 99.0명인 반면, 중산층 국가는 61.1명에 불과합니다.
또한 인도심장학회(CSI)에 따르면 인구 13억 명의 인도에는 5,500명의 심장 전문의가 있으며, 인구 3만 명당 1명의 심장 전문의가 있습니다. 또한 미국 의과대학협회(AAMC)의 최근 조사에 따르면, 2034년까지 이 나라에는 3만 7,000명에서 12만 4,000명의 의사가 부족할 것으로 예측됩니다. 그 중 일차 진료 의사는 17,000명에서 48,000명, 순환기 전문의는 3,000명에서 13,000명이 부족할 것으로 예상했습니다.
Intracardiac Echocardiography (ICE) utilizes sound waves to construct pictures of the heart in the exact manner that a transthoracic or "standard" echocardiogram accomplishes. Nevertheless, with intracardiac echocardiography, a small catheter with an ultrasound sensor is inserted into the heart where perfect pictures of the heart can be acquired to aid in diatinct cardiological condition diagnosis and management.
The Intracardiac Echocardiography (ICE) is a unique catheter imaging technology usually utilized to aid closure techniques for atrial septal defects (ASD), patent foramen ovale (PFO), and ventricular septal defects (VSD), interventions exclusively conducted as open-heart surgical operations a few years ago. Intracardiac echocardiography is vastly employed to direct transcatheter interventions for structural cardiac disorder and arrhythmia, to streamline procedural success and minimize intricacies.
The growing cases of cardiovascular disorders, market developments including mergers, acquisitions, products introductions among others, growing awareness among other factors are expected to boost the global intracardiac echocardiography devices market growth in the forecast period. Further, the growing research activities, technological advancements and with fundings in intracardiac echocardiography devices are also expected to contribute to the global market growth in the forecast period.
Dynamics
Increasing Prevalence of Cardiovascular Disorders
The growing cases of cardiovascular condition is among the primary factor that is expected to boost the global market growth in the forecast period. For instance, according to the European Cardiovascular Society, over 12.6 million individuals suffer from CVD each year in ESC-associated nations. The cardiovascular condition is the top reason for mortality (39%) among men in ESC member nations while 2.2 million females die because of cardiovascular condition annually in ESC associate nations around 40% of women die from CVD in the EU.
Also, according to the British Heart Foundation Released UK Factsheet in April 2023, around 7.6 million individuals are living with heart and circulatory disorders in the UK, aging and growing inhabitants and enhanced survival rates from heart and circulatory events could witness these numbers advance still additionally. About 4 million men and over 3.6 million women are living with heart and circulatory conditions in the UK, it is estimated that in the UK over half of inhabitants will encounter heart or circulatory disorders in their lifespan.
Moreover, approximately double the number of individuals living with heart and circulatory conditions in the UK compared to the number of cancer and Alzheimer's conditions cases added. Heart and circulatory disorders generate about 25% of all deaths in the UK; that's over 160,000 deaths annually, or 460 every day accounting for one death every three minutes, roughly 48,000 individuals below the age of 75 in the UK die because of heart and circulatory disorders every year.
Increasing Number of Product Approvals
The rising number of product approvals by distinct regulatory authorities is also expected to contribute to the global intracardiac echocardiography devices market growth during the forecast period. For instance, in April 2022, Franklin Mountain Medical obtained FDA authorization for its patented UltraNav Transseptal Catheter System a dual-lumen catheter that allows side-by-side, concurrent delivery of both ICE and transseptal needles or catheters via one dual-lumen device for steady access and delivery of cardiovascular catheters and guidewires to the cardiac chambers through transseptal puncture.
Similarly, in June 2021, Siemens Healthineers acquired CE Mark for the AcuNav Volume ICE (Intracardiac Echocardiography) catheter, a therapy-enabling imaging guide that delivers real-time, wide-angle visualization of cardiac anatomy in Structural Heart and Electrophysiology operations. AcuNav Volume ICE was the market's foremost Volume ICE catheter, designed based on 20 years of innovation record in ICE.
High Intracardiac Echocardiography Device Cost
The high intracardiac echocardiography devices and catheter costs are expected to be hampering the global Intracardiac Echocardiography Devices market growth during the forecast period. For instnace, the cost of a phased-array ICE catheter varies from $2,000 to $2,500, based on the volume of catheters bought. Similarly, the average list cost of cardiac 3D mapping systems varies from USD 250,000 to 800,000.
Likewise, Boston Scientific's iLAB Ultrasound Imaging System for Intracardiac Imaging costs around $131,400. Further, the average cost of a intracardiac echocardiography catheter system (USD 2000-2500) is an important barrier to the general usage of intracardiac echocardiography, slowing the global intracardiac echocardiography devices market demand in the forecast period.
Cardiologists Workforce Shortage
The cardiologists' workforce gap is expected to hamper the global intracardiac echocardiography devices market growth during the forecast period. For instance, according to the American College of Cardiology Foundation with not sufficient clinicians available to satisfy the requirements of an ever-growing patient population, the cardiology specialty domain is on the cusp of a concern. Similarly, according to the European Society of Cardiology in high-income nations, the median number of cardiologists per million inhabitants was 99.0 compared with 61.1 in middle-income nations.
Further, according to the Cardiologists Society of India (CSI), there are merely 5500 cardiologists in the country with a population of 1.3 billion, and there is only one cardiologist for the 30, 000 inhabitants in the nation. Again, according to a recent investigation from the Association of American Medical Colleges (AAMC), by 2034, the nation is predicted to be lacking anywhere from 37,000 to 124,000 medics. This contains a deficit of 17,000 to 48,000 primary care doctors and 3,000 to 13,000 experts, a category that encloses cardiologists.
The global intracardiac echocardiography devices market is segmented based on product type, imaging type, application, end-user and region.
3D Imaging Type Expected to Dominate Market
The increasing adoption of 3D intracardiac echocardiography (ICE) is expected to boost segmental growth enabling the segment to hold a majority of market share in the forecast period. For instance, in September 2022, Baptist Health's Miami Cardiac and Vascular Institute employed the VeriSight Pro, a real-time 3D intracardiac echocardiography catheter from Philips. The technology delivers exceptional 2D and 3D live imaging suggestions for a broad spectrum of cardiac operations in structural heart conditions.
Similarly, in December 2021, the Children's Hospital Colorado (Children's Colorado) was the foremost pediatric clinic in the globe to employ a 3D intracardiac echocardiography (ICE) catheter in the therapy of congenital heart conditions in the Cardiac Catheterization Lab. The live, 3D picture direction delivered by the FDA-authorized technology from Phillips permits cardiac interventionalists to sufficiently guide complicated operations, which is anticipated to result in enhanced outputs.
Geographical Penetration
Increasing Number of Cardiovascular Disorders Cases in North America
Owing to the growing cases of cardiovascular diseases in North America the region is expected to dominate the global market throughout the forecast period. For instance, according to the CDC, cardiac condition is the top reason for mortality of males, females, and individuals of most ethnical and racial levels in the United States, one individual dies every 33 seconds in the United States from cardiovascular condition.
Similarly, almost 695,000 individuals in the United States died from heart conditions in 2021 accounting for 1 in every 5 deaths. Further, the heart condition cost the United States around $239.9 billion annually from 2018 to 2019, which includes the expense of healthcare assistance, medications, and failed productivity because of death. Further, the American Heart Association has published the Heart and Stroke Statistics 2022 Update, according to that report, cardiac arrest remains a public health emergency as are over 356,000 out-of-hospital cardiac arrests (OHCA) yearly in the U.S., and almost 90% of them are deadly.
The incidence of EMS-assessed non-traumatic OHCA in individuals of any age is assessed to be 356,461, or almost 1,000 individuals every day. Survival to hospital release after EMS-treated cardiac arrest declines by approximately 10%. Additionally, in 2022, an estimated 655,000 Americans were expected to die because of heart conditions, and over 140,000 were expected to die from stroke. Accounting for one in every four deaths in the U.S. Heart condition and stroke also account for over $320 billion in healthcare expenses and failed productivity per year.
The COVID-19 pandemic had deep effects on cardio-pulmonary health and healthcare delivery. Direct effects enclosed information on myopericarditis jointly with highly regular information on pneumonia and pulmonary fibrosis, periodically advancing to respiratory collapse and demise. Additionally unpredictable, nevertheless, were the indirect effects of the pandemic on CV examinations and hospital admissions which have repeatedly demonstrated varying drops.
While there has been no indication of actual declines in the preponderance of CVD or the incidence of acute coronary syndromes, these reductions have extended considerations that the pandemic has directed to general under-investigation and under-treatment of many individuals. Indeed, reports from respective nations suggest substantial declines in investigative procedures for heart failure and coronary and electrophysiological conditions in 2020 corresponded with 2019. Declines in hospital admissions for a degree of CV conditions, including ST-elevation myocardial infarction, have even been registered in the same period.
The major global players in the market include Johnson & Johnson Services Inc., GE HealthCare, Koninklijke Philips N.V., Siemens Healthcare, Abbott Laboratories, Boston Scientific Corporation, Infraredx Inc., Terumo Corporation, ESAOTE SPA, and Conavi Medical among others.
The global intracardiac echocardiography devices market report would provide approximately 61 tables, 58 figures and 186 Pages.
LIST NOT EXHAUSTIVE